McKinsey $207 Million Settlement: Opioid Crisis Class Action Details

In the wake of the opioid epidemic, a significant class action settlement has been reached with McKinsey & Company, Inc. This settlement addresses claims that McKinsey played a pivotal role in the crisis by advising opioid manufacturers on marketing strategies. As a result, a $207 million fund has been established to benefit eligible political subdivisions in the United States. If you represent a government or special district, you may be entitled to a portion of this settlement to aid in opioid epidemic abatement efforts. The official settlement website provides detailed information and instructions for potential claimants.

Who Benefits?

Eligible entities include General Purpose Governments, Special Districts, and other subdivisions within the U.S. that meet specific criteria outlined by the settlement.

How much can I get?

The exact amount each entity can receive will depend on an allocation formula, with the funds earmarked for opioid remediation activities.

Important Dates

• Fairness Hearing: The court has scheduled a hearing for February 2, 2024.
• Deadline to File a Claim: Exclusion requests must be submitted by January 5, 2024. The settlement website does not specify a claim deadline, indicating that eligible subdivisions will automatically receive benefits unless they opt out.

Identifying Eligible Class Members

The class action lawsuit defines eligible members as General Purpose Governments and Special Districts within the U.S., as well as other subdivisions or officials acting on their behalf. These entities are represented by appointed Subdivision Class Counsel, and no action is required to receive benefits from the settlement, unless a subdivision wishes to be excluded.

• General Purpose Government in the U.S.A.
• Special District within a State
• Other subdivision or subdivision official

The lawsuit excludes sub-entities of certain territories and school districts.

Understanding the Settlement Award

The $207 million settlement fund is allocated among eligible class members based on a formula consistent with prior opioid settlements. The funds are designated for uses that directly address the opioid crisis, as stipulated in the settlement agreement.

• Direct payments to Subdivisions
• Attorneys’ fees and costs

The Opioid Crisis and McKinsey's Involvement

McKinsey & Company, Inc. is alleged to have significantly contributed to the opioid crisis by advising manufacturers on how to maximize opioid sales. The company denies these allegations, but the settlement aims to provide resources for combating the ongoing epidemic.

Is Proof Required to Claim the Reward?

Claimants are not required to submit specific proof to receive settlement funds. However, the funds must be used for approved opioid remediation purposes.

How to Claim Your Award

Eligible subdivisions do not need to take any action to receive benefits. To exclude your subdivision or object to the settlement, visit the official settlement website.

Analyzing the $207 Million Settlement

The settlement amount was negotiated to provide financial resources for opioid abatement efforts. The allocation formula ensures equitable distribution to eligible class members.

The Path to Settlement

The class action against McKinsey & Company, Inc. stems from the company's alleged role in exacerbating the opioid crisis. With the settlement reached, the next steps include the fairness hearing and the court's final approval.

For more information or to take action regarding the settlement, please visit the official settlement website.